<DOC>
	<DOCNO>NCT02858440</DOCNO>
	<brief_summary>The purpose study evaluate immune response , safety reactogenicity receive combine DTPa-IPV/Hib vaccine administer three-dose primary vaccination course 3 , 4.5 6 month age booster dose 18 month age Russian healthy child accord Russian immunisation schedule</brief_summary>
	<brief_title>A Study Assess Immunogenicity Safety GSK Biologicals ' Infanrix® -IPV/Hib Vaccine Administered Three-dose Vaccination Course 3 , 4.5 6 Months Age Booster Dose 18 Months Age Healthy Infants Russia</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representatives [ LARs ] , opinion investigator , comply requirement protocol . A male female child 3 4 month age time first vaccination . Written inform consent obtain parents/LARs subject prior perform study specific procedure . Healthy subject establish medical history clinical examination enter study . Born fullterm . Child care Use investigational nonregistered product study vaccine period start 30 day first dose study vaccine , plan use study period . Any medical condition judgment investigator would make intramuscular injection unsafe . Chronic administration immunosuppressant immunemodifying drug period start since birth . For corticosteroid , mean prednisone ≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period Planned administration/administration vaccine foreseen study protocol period start 30 day first dose end 30 day last dose vaccine administration , exception hepatitis B vaccine give part national immunisation schedule part routine vaccination practice , allow time study period . Seasonal pandemic influenza vaccine give time study , accord Summary Product Characteristics national recommendation . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis Hib diseases . History diphtheria , tetanus , pertussis , poliomyelitis Hib disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect . Serious chronic illness . History neurological disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature ≥37.5°C oral , axillary tympanic route , ≥38.0°C rectal route . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>19 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Primary dose</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Booster dose</keyword>
	<keyword>Combined vaccine</keyword>
	<keyword>Russian Infants</keyword>
	<keyword>Infanrix®-IPV/Hib</keyword>
</DOC>